title: Epithelial ovarian carcinoma in the reproductive age group.
abstract: BACKGROUND
  A retrospective review of women age < or = 40 years with epithelial ovarian carcinoma was undertaken to determine whether patient age and tumor grade are independent prognostic factors for survival, to investigate the survival rate for young women with ovarian carcinoma, and to characterize these young women in terms of reproductive capability.
  
  
  METHODS
  The tumor registry of the Massachusetts General Hospital was used to identify cases of ovarian carcinoma diagnosed between January 1980 and July 1996. Patient records and pathology were reviewed. Survival rates were calculated by the Kaplan-Meier method and Cox proportional hazards models were used to determine the independent effect of each variable on survival.
  
  
  RESULTS
  Ninety-two tumors epithelial tumors were identified with 46 (50%) classified as borderline. In the univariate analysis, stage (P < 0.001), grade (P < 0.001), residual disease (< or = 2 cm vs. > 2 cm, P < 0.001), and age (< 30 years vs. 31-40 years; P = 0.019) were found to be significant prognostic factors for survival. However, in the multivariate analysis only tumor grade (with borderline tumors assigned a grade of 0) and stage were significant predictors of survival (P < 0.01 for both). The 5-year survival rate for carcinoma patients with advanced disease was 22.9%. Patients with borderline tumors were more likely be diagnosed during an evaluation for infertility and were more likely to have successful live births after carcinoma treatment.
  
  
  CONCLUSIONS
  Young women with advanced epithelial carcinoma have a 5-year survival rate similar to that quoted in the literature, despite the use of more aggressive chemotherapeutic regimens. Patients with borderline tumors of any stage have an excellent prognosis for preserving fertility options.
authors.affiliation: Vincent Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital, Boston 02114-2617, USA.
authors.forename: L R
authors.initials: LR
authors.lastname: Duska
authors.forename: Y C
authors.initials: YC
authors.lastname: Chang
authors.forename: C E
authors.initials: CE
authors.lastname: Flynn
authors.forename: A H
authors.initials: AH
authors.lastname: Chen
authors.forename: A
authors.initials: A
authors.lastname: Goodman
authors.forename: A F
authors.initials: AF
authors.lastname: Fuller
authors.forename: N
authors.initials: N
authors.lastname: Nikrui
mesh_terms: D000328:Adult; D017668:Age of Onset; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D004848:Epithelium / Q000473:pathology; D005260:Female; D005298:Fertility / Q000187:drug effects; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D016019:Survival Analysis